Key clinical point: Patients with multiple myeloma who are aged 70 years and older should be considered for upfront autologous hematopoietic cell transplantation (AHCT).

Major finding: Patients aged 70 years and older who received upfront AHCT had similar nonrelapse mortality, relapse/progression, progression-free survival, and overall survival, compared with a reference group of patients aged 60-69 years.

Study details: An analysis of outcomes from 15,999 multiple myeloma patients aged 20 years or older in the United States who received a single AHCT with melphalan conditioning within 12 months of diagnosis between 2013 and 2017.

Disclosures: Study authors reported financial relationships with multiple companies including Celgene, Takeda, BMS, and Janssen.